Compare Novartis AG (NVS) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Vale SA — how do they compare? Novartis AG trades at $138.17 (market cap $262.64B), while Vale SA trades at $15.42 (market cap $65.56B). The key difference: Novartis AG is far larger — about 4× Vale SA's market cap, and Vale SA pays the higher dividend (7.65%). Which is the better fit depends on your goals.
| NVS | VALE | |
|---|---|---|
Market Cap | $262.64B | $65.56B |
Sector | Health | Basic Materials |
52-Week High | $168.62 | $17.82 |
52-Week Low | $121.80 | $10.50 |
Enterprise Value | $303.97B | $81.80B |
Dividend Yield | 3.44% | 7.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.
While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.
VALE trades at $15.56, up 1.9% on the day, with a bullish technical signal from moving averages and a consensus price target of $16.79. Recent earnings missed estimates for Q4 2025 and Q1-Q2 2026, with net income margin declining to 5.11% in 2025. The company maintains strong operating cash flow of $8.80B and announced a $0.40 dividend for H2 2026. Iron ore demand remains stable per the CFO, while base metals growth offsets cost pressures.
VALE presents a mixed outlook: bullish technicals and analyst support contrast with earnings misses and margin compression. The stock offers value near consensus targets with dividend income, but faces risks from rising costs, volatile commodity prices, and legal liabilities from past dam incidents. Upside depends on execution in copper growth and cost control.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
